chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient is a 85 y.o. male with a history of CLL, DM2, CAD, recent ED visit 9/14/23 s/p fall, found to be COVID-19 positive who presented to Hospital 9/17/2023 with worsening cough, fatigue, weakness, and intermittent confusion. He was treated with decadron for covid.      1. COVID-19: Presented as above. Symptom onset 9/14/23, positive test 9/14/23. Vaccinated. CXR with unchanged left basilar opacity (compared to 9/14/23). Initially not needing supplemental oxygen, now on NC. Stopped decadron 9/20 as patient weaned off O2.  2. Acute Hypoxic Respiratory Failure: secondary to Covid, mild and only requiring 2L NC, treatment of Covid as above. Patient weaned off O2 9/20 as above. Resolved.  3. Generalized weakness: Patient with generalized weakness/fatigue. Likely related to viral illness. Supportive measures, PT/OT/CM following. Plan for SNF at discharge.  4. Acute Metabolic Encephalopathy: presented as above, suspect combination of viral illness and hypoxia. Afebrile, no leukocytosis. Supportive care, delirium prevention measures. Decadron as noted but will monitor for side effects. Stopped decadron. Melatonin ordered. Hospital delirium likely contributing. Will trial trazodone 9/21 due to continued delirium and sleep deprivation. Encourage sleep hygiene. Delirium precautions.  Improved with trazodone. DC on trazodone prn.  5. CAD: Per history with prior MI, s/p LHC in 2001, 2007, last LHC 05/2018 with DES to prox circumflex and mid/proximal LAD. Continued home ASA/statin. 6. NIDDM2: HgbA1c 7.5 6/7/23. Held home Metformin on admit, initiated SSI while inpatient. Monitor and titrate as needed.  Improving off of decadron. Adjusted prandial insulin with continued hyperglycemia. Resolved.  7. Gait ataxia: Per history, follows with Dr. (neurology), thought to be sensory ataxia due to DM, CLL, and chemotherapy. Reports multiple recent falls. Supportive care with PT/OT.  8. Mild cognitive impairment: Per history, follows with Dr. (neurology), with short term memory loss. Delirium precautions. 9. CLL, thrombocytopenia: Per history, follows with Dr. (oncology). Completed 6 cycles Obinutuzumab 10/19/21. Admit Platelets 132, Hgb 13. Recommended continued outpatient follow-up with oncology. 10. Mild Hyponatremia: Admit Na 129. Suspect due to dehydration on presentation. Improved w/ IVF in ED. Daily BMP.  11. Code status: Full
2nd varicella vaccine given on 1.25.17. The next day, she noted a red area, size of a quarter with itching, pain and enlargement of erythematous area. She also reported fatigue, global headaches and generalized itching, including hard palate in her mouth. She reports history of anaphylaxis and "this did not feel like it". She took RU-HIST 3 times, which helped. Assessed by medical provider in Occupational Health on 1/27/17, diagnosed with localized reaction to vaccine. On 1/28/17, evaluated at Medical Center. She reported increased swelling to injection site (left upper arm) spreading to axillary area with vesicular eruption. Treated with KENALOG 80 mg IM. ED provider also noted positive Herpes Zoster eruption. Rx given for VALTREX; ULTRACET; Amitriptyline.  On 1/31/17, returned to Lavaca Medical Center with concern of face edema "face feels like it is on fire" and "possible blister in mouth" but per ED notes: "noted facial redness/rash, but no facial edema or sores in mouth".  Given Rx for Atarax 25 mg 1-2 tabs q6h as needed.  On 3/09/17, evaluated at Concentra Medical Center, given refill of Amitriptyline and was cleared to return to work at full duty.  On 3/10/17, evaluated at Seton Occupational Health for a clearance to return to work, since she had areas that could not be covered with clothing. Provider noted- no lesions to face or neck, but had some swelling and erythema to neck and left axilla.  Diagnosis: Systemic Reaction to Varicella Vaccine  On 5/02/17-Associate did not return for follow up and resigned employment
lost sense of smell; This spontaneous case was reported by an other health care professional and describes the occurrence of ANOSMIA (lost sense of smell) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L00A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in September 2020.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced ANOSMIA (lost sense of smell). At the time of the report, ANOSMIA (lost sense of smell) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. This spontaneous case was reported by an other health care professional and describes the occurrence of ANOSMIA (lost sense of smell) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L00A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in September 2020.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced ANOSMIA (lost sense of smell). At the time of the report, ANOSMIA (lost sense of smell) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  No treatment information was provided.  Company comment: Based on the current available information and temporal association between the use of the product and the onset date of the reported event, a causal relationship cannot be excluded.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the reported event, a causal relationship cannot be excluded.
Headache soon after shot. Headache lasted two days. Swelling in arm for a week. Day 2, chills with flu like symptoms.
Patient's arm swelled up and a rash began running down the left arm.  It was very itchy.  Patient received antibiotics from physician.
Dental procedure; This spontaneous case was reported by a consumer and describes the occurrence of DENTAL OPERATION (Dental procedure) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DENTAL OPERATION (Dental procedure). At the time of the report, DENTAL OPERATION (Dental procedure) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       no relevant concomitant medications was reported. No treatment information was provided
Patient received her first Pfizer dose on February 2, 2021 and reported an itchy rash that developed shortly after receiving the vaccine. She said she took Benadryl after the rash developed but it did not relieve her symptoms. Patient received her second dose of Pfizer on February 20, 2021 and did not report any reaction after that dose. Within 10 minutes of receiving her third Pfizer vaccine, she reported red itchy areas on her inner arms. As she was describing this, the rash began to develop around her neck and chest and became more red and itchy. She did not report any trouble breathing or swelling of lips or tongue. Patient did not want to take Benadryl because she said it did not work after having similar symptoms after her first dose. Per Pharmacy protocol for vaccines, the emergency service was called because of the generalized reaction. Patient sat in a chair at the pharmacy for approximately 15  minutes until the emergency services came, they monitored her for approximately 15 more minutes, then she left to go home with her husband to drive her home.
Diarrhea, fever, vomiting, horrible itchy rash all over the body, ended up getting severely dehydrated on 6/25/2011 and had to be hospitalized for 1 night.
Approximiately 10 days after receiving the second dose of the moderan covid vaccine, patient experienced symptoms consistant with Bells Palsy with facial dropping. Patient was treated in the emergency department using antiviral therapy. The condition is new and currently unresolved.
About 8-10 minutes after the injection, my vision got blurry. It was very brief- only a couple minutes long. If it had lasted until the end of my 15 minute post-injection observation period, I would have reported it then, but it didn't. I decided to include it here, because later in the day, I had another reaction. About 12 hours after the dose -around 7PM- I started getting chills and body aches and abnormally fatigued. The chills were intense almost as soon as they come on. The body aches were mild for the first couple hours and progressed to intense. Both symptoms lasted continuously for about 12 hours, then around 7AM they started to wane. I'm not sure if I should list insomnia as a reaction, but despite how exhausted I felt, I could not sleep. It could have also been just general discomfort that kept me from being able to sleep. Through most of the following day I had mild aches and waves of chills. By the time I went to bed that night (last night at the time of writing this), the symptoms had mostly  cleared and so far have not returned.
I was 10 weeks and 3 days pregnant. Estimated due date was 3/6/22. I had a miscarriage with no history of miscarriages.
On May 4th, the day following the vaccination, I noticed an enlarged itchy spot on right of center forehead above the right eye. At first I suspected poison ivy but by the third day the site was, reddening, swelling and sore. There was increasing sensitivity on right side of face alongside my eye. By May 7th, I was very suspicious that I was experiencing shingles symptoms. On May 8th, I returned to the pharmacist who administered the vaccination. He said that symptoms of shingles was not in the literature and that I'd received a killed virus. On May 9th at 8:30 AM, I consulted with my dermatologist who confirmed that I have shingles and prescribed a 9 day course of the antibiotic Valacyclovir HCL. I've taken facial photos to document the occurrence.
On 7/1/06 c/o increase pain, redness, swelling R elbow and under arm, temp 100 felt weak. Sought ED tx placed on Keflex with improvement is SX of cellulitis.
Swollen lymph after 5 days on my neck  However it is not painful and it has become smaller compare to what I found
severe eye pain; This case was reported by a consumer via interactive digital media and described the occurrence of eye pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 23rd October 2020, the patient received Shingrix. On 24th October 2020, 1 days after receiving Shingrix, the patient experienced eye pain. On an unknown date, the outcome of the eye pain was not recovered/not resolved.   It was unknown if the reporter considered the eye pain to be related to Shingrix.  Additional details were reported as follows: This case was reported by the patient. The age at vaccination was not reported. The age group was not reported but was selected as an adult as per vaccine indication. A day before reporting, the patient received Shingrix vaccine. On the day of reporting, the patient was having severe eye pain and asked what could be done.
6/20/13 painful (L) deltoid; treated with ice locally, MOTRIN p.o. 6/22/13 (L) deltoid: swelling from elbow to shoulder, sl. red/itchy, took pt to urgent care, dx: local vaccine reaction, prescribed prednisone BID x5 days and naprosyn. 6/26/13: completely better.
Itching near injection site; Arm turned red near injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Itching near injection site) and VACCINATION SITE ERYTHEMA (Arm turned red near injection site) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, the patient experienced VACCINATION SITE PRURITUS (Itching near injection site) and VACCINATION SITE ERYTHEMA (Arm turned red near injection site). At the time of the report, VACCINATION SITE PRURITUS (Itching near injection site) and VACCINATION SITE ERYTHEMA (Arm turned red near injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details were reported.  The patient reported treatment included ice.   Most recent FOLLOW-UP information incorporated above includes: On 07-Jun-2021: Follow up received:No New Information. Confirmed patient information, event details and vaccine inforamtion.
9/30/19: child had genital swelling  and ankle edema 10/18/19: worsening ankle edema and periorbital edema
overall fatigue and muscle soreness with low grade fever and chills.; overall fatigue and muscle soreness with low grade fever and chills.; overall fatigue and muscle soreness with low grade fever and chills.; overall fatigue and muscle soreness with low grade fever and chills.; This is a spontaneous report from a non-contactable other HCP (patient, self reported). A 36-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, formulation: solution for injection, lot number: Er8733 and expiry date was not reported), via an unspecified route of administration, in left arm, on 29Mar2021 05:45 PM, as DOSE 1, SINGLE for COVID-19 immunization (Age at vaccination: 36years). Facility type vaccine was other. The patient was not pregnant at the time of vaccination. The patient medical history included known allergies: Haldol. Concomitant medications included ibuprofen (MOTRIN). The patient did not receive any other vaccine in four weeks. The patient was not diagnosed with COVID prior vaccination. The patient was tested for COVID post vaccination. The patient experienced overall fatigue and muscle soreness with low grade fever and chills on an unspecified date in 2021. The AE did not result in emergency room or physician office. The patient did not received treatment for the events. The patient underwent lab test and procedure included covid test type post vaccination: Nasal Swab with negative result on an unspecified date. Outcome of the events were recovered on an unspecified date.  No follow-up attempts are possible. No further information is expected.
I started to have abnormal vaginal bleeding 8 days after receiving the vaccine. The blood did not stop until I had surgery. This continued for 11 months. This has never happened to me and only started to happen after I received the vaccine.
Shortly after my arm was very sore for a few days.  A few couple weeks later I noticed a rash on the inner left arm which by the next morning afte had spread all over my entire body and was very itchy.  On 1/13 my PCP diagnosed it as ezema and prescribed cortosone cream.  I began experiencing Asthma issues so my PCP prescibed prednisone to help with that and the rash cleared up about 4 days later
Information regarding Flumist (2003-2004 Formula) (influenza virus vaccine, live intranasal (2003-2004 formula) nasal solution (frozen)) was received from a healthcare professional regarding an adult female patient who experienced itchy eyes about 5 minutes after receiving Flumist. The patient received a dose on an unspecified date. Medical History: Relevant medical history was not provided. Product Details: Indication for Flumist (2003-2004 Formula) was immunisation. Product was administered on an unspecified date. Dose regimen was 1 dose. Concomitant Therapy: Concomitant medications were not reported. Event Details: The patient experienced itchy eyes about 5 minutes after receiving Flumist. As soon as she itched her eyes, there were fine. The reporter indicated that the patient's son also experienced this same event. Related case(s): See related case: HQWYE753718DEC03 (adverse event, non-expedited). No additional information was available at the time of this report.
Pt received flu vaccine (FLUZONE Quad) and PNEUMOVAX 23 both same day same arm (1" apart) 4 days later still had red mark, sore arm, slight raised area.
After receiving Td and hep B vaccines client passed out-was placed in supine position with feet elevated. DP first reading 90/60, checked BP evening 5min, PB readings 110/80 and 120/80 HR 80. Client drank orange joice  and ate crackers. BP stable after 15-20 minutes; left clinic with parents.
Diarrhea; Intense muscle and joint pain; Intense muscle and joint pain; Severe fatigue - very distinct; This is a spontaneous report from a non-contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history and had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 25Aug2021 at 01:00, the patient experienced diarrhea, intense muscle and joint pain and severe fatigue - very distinct. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events diarrhea, intense muscle and joint pain and severe fatigue - very distinct was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Swelling from my elbow to shoulder, red, itching, headache and sore neck
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021 at 11:12 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 07-Jan-2021 at 11:12 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 86.29.  Concomitant products were not provided.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Awoke morning after vaccine with grape size lump left next to left clavicle at nape of neck with tenderness. Had similar reaction in 2006, but was not reported.
pt recv vax 5JAN96 & 8JAN96 pt devel a local rxn @ inj site approx 5cc-swelling, red, hot;no further details were provided
After the Moderna #1 I had a reoccurance of chronic urticaria and have had daily outbreaks since. Prior to vaccine I had 1+ years symptom free and managed with 100mgs of Dapsone. Since reoccurance of hives dapsone increased to 150mgs daily, still having daily outbreaks, but improved with dose increase.
Patient wanted a booster with Moderna after their initial vaccination with Janssen. Patient received  Janssen in error instead of Moderna. No adverse effects observed.
felt a little punky; fatigue; body aches; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (felt a little punky), FATIGUE (fatigue) and MYALGIA (body aches) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma, Fibromyalgia, Arthritis and Food allergy (breaks in hives in response to foods).   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (felt a little punky), FATIGUE (fatigue) and MYALGIA (body aches). At the time of the report, VACCINATION COMPLICATION (felt a little punky), FATIGUE (fatigue) and MYALGIA (body aches) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications included inhaler.  No treatment medications were reported for second dose.   This case was linked to MOD-2021-307220, MOD-2021-307256 (Patient Link).
Cellulitis as diagnosed by practitioner red inflamed rash radiating from just below shoulder to blow elbow (approximately 8 inches by 4 inches), itchy, irritation. Reaction caused by Zostavax, flu shot site not affected.
Admit 8/1, vaccine 2/27, 3/24. Presented w/AMS, lethargy, fatigue. Hx or DM, HTN, CAD. CXR showed PNA, pos COVID test. Treated with O2, steroid, antibiotic, and remdesivir. At DC did not require any O2 w/ambulation. DC'd to home.
leg cramps; headache; This spontaneous case was reported by a consumer and describes the occurrence of MUSCLE SPASMS (leg cramps) and HEADACHE (headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 2 dosage form. On 13-Apr-2021, the patient experienced MUSCLE SPASMS (leg cramps) and HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) ongoing since an unknown date for Headache, at a dose of UNK dosage form. At the time of the report, MUSCLE SPASMS (leg cramps) and HEADACHE (headache) outcome was unknown.            Reporter provided only limited adverse event data as the agent could not provide any medical advice.